Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyWellfleet PRP Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentWellfleetPolicy GL-019

    Platelet-Rich Plasma Injections

    Customize your policy alerts

    Sign up for wellfleet Policy GL-019 alerts

    Get alerted when Policy GL-019 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This payment guideline describes how Wellfleet evaluates and reviews platelet-rich plasma utilization for specified orthopedic and musculoskeletal conditions across applicable commercial, student, casualty, fully insured, and self-funded plan arrangements, subject to the member benefit document and provider agreement.

    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateJan 25, 2023
    Next Review DateSep 1, 2023
    Key ActionSubmit unlisted PRP utilization for physician review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11Specific PRP utilization areas
    3Evaluation outcomes
    Physician reviewUnlisted utilization review
    May be requestedSupporting records
    ApplicableApplicable plan arrangements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PRP Evaluation Criteria

    Diagnosis- and procedure-specific PRP evaluation

    The following grid describes the evaluation and disposition for specified PRP utilization. Results are approval after RN review, referral for physician review, or investigational/experimental. Any utilization not listed requires physician review.

    Achilles tendinopathy: Investigational/experimental. Randomized trials cited by the guideline failed to show superiority of PRP over placebo or physiotherapy.
    Achilles rupture: Investigational/experimental. The guideline states that surgical treatment is required for Achilles tendon rupture.
    Ankle osteoarthritis injections: The grid contains both an approval-after-RN-review marker and an investigational/experimental marker. Supporting information cites a 2021 randomized trial showing no significant improvement versus placebo, while other small studies reported positive findings with important limitations.

    Source table contains conflicting disposition markers; preserve for physician interpretation.

    Anterior cruciate ligament injury or reconstruction, nonsurgical: Approve after RN review when the request is for injection without surgery; the guideline cites two studies with positive results. Intraoperative or surgical ACL reconstruction use is investigational/experimental because systematic reviews found no beneficial clinical, graft-integration, or tunnel-enlargement outcomes.

    Separate nonsurgical injection from surgical or intraoperative reconstruction use.

    Patellar tendon ACL reconstruction donor site: Approve after RN review for surgical application at the patellar tendon harvest site; cited studies reported improved healing and pain.
    Knee osteoarthritis injections: Investigational/experimental. The RESTORE randomized clinical trial cited in the guideline found no significant difference from saline placebo in symptoms or joint structure at 12 months.
    Lateral epicondylitis: Disposition depends on PRP formulation: leukocyte-rich PRP is marked for approval after RN review, while use without leukocyte-rich PRP requires physician review. The guideline describes inconsistent and contradictory evidence overall.

    Confirm whether the request involves leukocyte-rich PRP.

    Meniscal tears: Investigational/experimental. The guideline cites few, small, and contradictory studies.
    Muscle injury: Refer for physician review. Evidence includes non-randomized studies suggesting improved tissue repair or functional recovery, but randomized trials showed controversial results.
    Patellar tendinopathy: Refer for physician review and identified as investigational/experimental in the grid. Evidence is described as minimal and conflicting, although one meta-analysis was highly positive for leukocyte-rich PRP.

    The grid contains both physician-review and investigational/experimental markers.

    Plantar fasciitis: The grid contains both an approval-after-RN-review marker and an investigational/experimental marker. Evidence is conflicting, generally low quality, and shows marginal or limited benefit.

    Source table contains conflicting disposition markers; preserve for physician interpretation.

    Rotator cuff injuries: Investigational/experimental is marked for the overall rotator cuff category. Supporting discussion describes PRP as a possible conservative alternative to corticosteroid injection for tendinopathy and partial tears; the source table distinguishes tendinopathy or partial tears from other tears.

    Confirm tear type and treatment context.

    Ulnar collateral ligament injury: Approve after RN review. Three small studies in athletes reported improved outcomes.

    PRP utilization not listed in the evaluation grid is not eligible for the listed RN disposition and requires physician review.

    Indications designated investigational/experimental in the evaluation grid are excluded from routine approval under the corresponding disposition and are handled according to the investigational/experimental designation.

    Provider Submission Requirements

    Prior Authorization

    Physician Review for Unlisted Use

    Any PRP utilization not listed in the evaluation grid requires physician review before a determination is made.

    • Submit the request for physician review when the diagnosis or procedure is not one of the eleven listed utilization areas.
    Documentation Required

    Supporting Claim Documentation

    Providers are responsible for submitting accurate claims. Wellfleet may request supporting documentation, including provider records, for claims submitted.

    • Ensure claim information accurately reflects the diagnosis, procedure, and PRP service provided.
    • Maintain and provide supporting clinical records when requested by Wellfleet.

    Policy Background

    Platelet-rich plasma (PRP) is evaluated for orthopedic and musculoskeletal conditions, including tendinopathies; ligament, meniscal, muscle, and rotator cuff injuries; osteoarthritis; plantar fasciitis; and related injection, surgical, and nonsurgical applications. The guideline’s evaluation reflects evidence that ranges from positive or potentially beneficial findings to inconsistent, negative, or insufficient evidence, with the disposition depending on the specific diagnosis or procedure and, in some cases, the PRP formulation or treatment context.

    Key Terms

    Definition 1
    TermSupporting information
    DefinitionInformation provided to support the evaluation of a PRP diagnosis or procedure.
    Grid designationIdentified as result category 1 in the PRP utilization evaluation grid.
    Definition 2
    TermApprove after review by RN
    DefinitionApproval after review by a registered nurse.
    Grid designationIdentified as result category 2 in the PRP utilization evaluation grid.
    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateJan 25, 2023
    Next Review DateSep 1, 2023
    Key ActionSubmit unlisted PRP utilization for physician review.
    SourceLink
    On This Page
    PRP Evaluation CriteriaProvider Submission RequirementsPolicy BackgroundKey Terms
    Documentation Required

    Clinical Request Details

    Clinical requests should identify the condition or procedure and describe the specific PRP utilization so the request can be evaluated under the applicable grid category.

    • Diagnosis or procedure being treated.
    • Specific PRP use, including injection, surgical application, or other utilization.
    • Relevant treatment characteristics, such as whether the request involves LR-PRP, an operative or nonoperative application, or the type and location of the injury.
    Denial Risk

    Unlisted Utilization May Require Physician Determination

    Unlisted PRP utilization is not eligible for the RN review pathway and requires physician review. The physician review may result in non-approval.

    • Do not assume RN approval for a utilization that does not appear in the evaluation grid.
    • Provide sufficient clinical information for physician review and determination.
    Denial Risk

    Investigational or Experimental Indication

    When the evaluation grid identifies a PRP indication as investigational or experimental, the request is handled under that disposition rather than approved through the RN review pathway.

    • Clearly identify the diagnosis or procedure and the requested PRP utilization.
    • Requests classified as investigational/experimental may not be approved or reimbursed under the guideline.
    • Supporting clinical records may be requested to evaluate the indication and treatment characteristics.
    Definition 3
    TermRefer for physician review
    DefinitionReferral for review by a physician.
    Grid designationIdentified as result category 3 in the PRP utilization evaluation grid; utilization not listed in the grid requires physician review.
    Definition 4
    TermInvestigational/Experimental
    DefinitionA PRP utilization designation indicating investigational or experimental status.
    Grid designationIdentified as result category 4 in the PRP utilization evaluation grid rather than routine RN approval.
    LR-PRP
    AbbreviationLR-PRP
    Full termHighly cellular leukocyte-rich platelet-rich plasma.
    Clinical contextThe guideline specifically distinguishes requests using LR-PRP from requests without LR-PRP for lateral epicondylitis.